Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides

PBAC's latest decision on Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides: Recommended with restriction (2015). Considered for Eosinophilic oesophagitis and severe intestinal malabsorption including short bowel syndrome (Alfamino®); eosinophilic oesophagitis (Alfamino® Junior).

Eligible population

Patients with eosinophilic oesophagitis or severe intestinal malabsorption including short bowel syndrome requiring amino acid based formula as part of dietary elimination program; age 18 years or less for eosinophilic oesophagitis indication.

Therapy area

Gastroenterology

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

Neocate® Gold (Alfamino®); Neocate® Advance (Alfamino® Junior)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no economic model provided for this minor submission.

Similar precedents

• Amino acid synthetic formula
  similarity 0.83
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids, medium chain triglycerides, 2'-fucosyllactose and lacto-n-neotetraose
  similarity 0.83
• Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids
  similarity 0.75
• Amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides
  similarity 0.74
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids
  similarity 0.71
• Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids; amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids
  similarity 0.71